Canadian drugmaker Aralez Pharmaceuticals (Nasdaq: ARLZ) has acquired the US and Canadian rights to US pharma giant Merck & Co’s (NYSE: MRK) blood-thinning drug Zontivity (vorapaxar).
Zontivity is the first and only approved therapy shown to inhibit protease-activated receptor-1 (PAR-1), the primary receptor for thrombin, which is considered to be the most potent activator of platelets.
Earlier this month, Merck announced it would be stopping promotion of the drug, which at one point was forecast to bring in $5 billion worth of sales, following the emergence of serious bleeding risks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze